1. Introduction {#s0005}
===============

Worldwide, cervical cancer continues to be a serious public health problem; with more than 500,000 new cases and 250,000 deaths occurring annually, 90% of them in middle-low income countries. ([@b0005]) In recent decades, Human papillomavirus (HPV) testing that detects sexually transmitted infection with oncogenic types of HPV, was developed as an alternative screening method. HPV testing has high sensitivity and negative predictive value, and it has been shown effective to reduce cervical cancer incidence and mortality. ([@b0010]) In addition, HPV testing allows for sample self-collection, which is effective in increasing screening uptake. ([@b0015]) At present, the World Health Organization recommends screening with HPV testing in combination with HPV vaccination as the main strategy to accelerate elimination of cervical cancer. ([@b0020]) Worldwide, more than 15 countries have introduced HPV testing in primary screening; ([@b0025]) in the Latin American region, Argentina and Mexico are using it as public health policy for cervical cancer prevention, and in most other countries in the region, pilot or demonstration projects are being implemented in order to move forward towards national implementation. ([@b0030], [@b0035]) High screening coverage as well as high adherence to follow-up recommendations and treatment are necessary in order to achieve a reduction in cervical cancer incidence. ([@b0020])

Prevalence of oncogenic HPV infection among women aged 30 and above is relatively high (9% in South America), ([@b0040]) so a significant proportion of screened women will be diagnosed with HPV infection. HPV testing identifies infection with an oncogenic type of HPV that cannot be treated; triage tests are used to identify HPV positive (HPV + ) women who will require diagnosis and treatment: only a portion of HPV + women will have a positive triage indicating a precancerous lesion requiring further evaluation ([@b0045]) (around 70%-88% in studies using cytology triage). ([@b0035], [@b0050]) Due to the HPV-test moderate specificity for detection of cervical precancer, ([@b0055]) most HPV + women will end up with an HPV+/triage negative result requiring repeat screening in 12/18 months. Thus, infection with an oncogenic type of HPV can be detected, but positivity does not necessarily mean that the infection will cause cervical precancer or cancer or that the woman will require treatment. In most women, HPV infections will resolve naturally.

Evidence has shown that as a result of all these characteristics HPV testing can have a negative psycho-social impact on women lives. ([@b0060]) In effect, as a consequence of the known sexual transmission of the infection, HPV positivity has connotations of promiscuity, stigmatization, impurity, and can result in shame, worries about future sexual relationships and questions about the women's or their partner's sexual behavior. ([@b0065], [@b0070], [@b0075]) HPV results can also produce anxiety, fear of death, and disease denial, or women not considering it necessary to continue diagnosis, treatment and follow-up. ([@b0080], [@b0085], [@b0090]).

It has been shown that believing that an abnormal screening test is indicative of cancer and inevitable death, in addition to its association with a sexually transmitted disease can act as barriers for diagnosis and treatment of precancerous lesions. ([@b0095], [@b0100], [@b0105]) Thus, HPV positivity can have a negative psycho-social impact on women lives which not only might result in poor quality of life but also reduce womeńs ability to complete diagnosis, treatment and follow-up.

However, in spite of the evidence about potential negative psycho-social impact of HPV testing as primary screening, no study from Latin America has quantitatively measured it using a validated scale specifically devised to measure it. We carried out the Psycho-Estampa study in Colombia and Argentina, aimed at developing a scale and measuring the psycho-social impact of HPV positivity in the context of cervical cancer prevention programs using HPV-testing as primary screening in Latin America. The Psycho-Estampa study is part of ESTAMPA, a multicentric study led by IARC-WHO aiming to evaluate different cervical screening and triage techniques using HPV (NTC 01881659). In this paper we present results of the psycho-social impact of HPV positivity of women HPV-tested in Jujuy, Argentina.

To our knowledge, this is the first evaluation of the psycho-social impact of HPV testing in the region using a validated scale specifically designed for Latin American women. Therefore, it constitutes key evidence for the design of strategies aimed at reducing impact and improving women's quality of life and increasing their ability to continue follow-up care.

2. Methods {#s0010}
==========

2.1. The setting {#s0015}
----------------

The study was carried out in the province of Jujuy, where HPV-testing has been the primary screening method since 2012, ([@b0035]) targeting women aged 30 years and older attending the public health system. HPV samples are collected by clinical staff at health centers, and since 2014 HPV self-collection was introduced as a programmatic strategy to increase screening coverage. Women are informed of their results at health care centers. The protocol in use in Jujuy has been described elsewhere ([@b0035]) but succinctly HPV + women are triaged with cytology; those with samples that include Atypical Cells of Undetermined Significance or more (ASCUS + ) are referred to colposcopy and biopsy if needed. Women with histologically confirmed CIN2 + are referred for treatment. HPV-negative (HPV-) women were recommended for rescreening in five years. HPV-testing and cytology-triage are taken simultaneously, but cytology is read only if women are HPV + . Women who are HPV + and have normal cytology, are recommended for rescreening in 18 months

The study population included women screened at the gynecology service at the Centro Sanitario Dr. Carlos Alvarado, a main hospital located in San Salvador de Jujuy, the provincial capital city. Around 6,000 women are HPV-tested annually in this gynecologic service. HPV + women with abnormal cytologies were referred to colposcopy and biopsy, those with cervical intraepithelial neoplasia (CIN) grade 2 or worse (CIN2 + ) on biopsy were adequately treated. Exclusion criteria were having cognitive or sensorial challenges.

2.2. Women eligibility {#s0020}
----------------------

Eligible women were HPV + women, aged 30--65 years old. From April 2015 to March 2016, eligible women were invited to participate in the study during the consultation for receiving the HPV results; those who agreed signed an informed consent and were contacted around 8 days later for a face-to-face or telephone interview by a trained interviewer.

2.3. Outcome measurement {#s0025}
------------------------

The psycho-social impact of HPV-testing was measured through the Psycho-Estampa scale, an instrument designed to measure the psycho-social impact of HPV tests within the framework of primary screening for cervical cancer. It consists of five domains with 22 items that were generated from a literature review and in-depth interviews with HPV + women and health personnel. ([@b0110], [@b0115]) The 22 items are evaluated with an ordinal system of 4 categories ranging from 1 (not at all) to 4 (much) and organized theoretically in five domains:1)Emotional domain, which measured impact related to women cognitive perceptions and feelings around having a sexually transmitted infection,2)Sexuality domain, which measured impact related to attitudes and practices regarding sexual relationships,3)Domain referred to the Uncertainty about information provided by health providers, which measured impact related to worries around the received messages and those related to the interaction with health professionals,4)Domain referred to Repercussions on the family, which measured impact related to fears about the transmission of the HPV to other members of the family,5)Domain about Worries about HPV, cancer and treatment, which measured impact related to worries about how the infection was acquired, its treatment and its association to cancer.

Higher scores on the scale indicate a higher negative psycho-social impact. The scale was validated for internal consistency, reliability, construct validity, test--retest, sensitivity to change and concurrent validity (See [Supplementary File](#s0090){ref-type="sec"} for a detailed description of the scale validation). Its structure and items can be seen in [Appendix A](#s0090){ref-type="sec"}.

2.4. Statistical analysis {#s0030}
-------------------------

Participating women were asked to score each Psycho-Estampa scale item to a 4-point discrete scale (1 = Not at all, 2 = A little, 3 = Some, 4 = Much). Women with no sexual partner at the time of the interview, were not asked the question regarding impact on sexual life. Women with no children at the time of the interview, were not asked the question regarding fear about transmission to children. The scores for each domain of the scale were computed as the average of the scores of the questions answered for that domain, not taking into account unanswered items (excluding missing values). To create the overall Psycho-Estampa score, the mean was computed as the sum of all the items over the number of items answered on all scale domains.

A mean total Psycho-Estampa score of 2 or below was interpreted as a domain with a tendency to be answered as little to no impact; a score of 3 was considered a trend to women answering moderate impact and a score of 4 was taken as indicative of heavy psycho-social impact.

Basic descriptive statistics and frequency calculations were performed on socio-demographic variables (age, number of sexual partners, education level) and cytology diagnosis. We also compared scores in each domain and the total score according to cytology-results. First, we grouped both abnormal categories of cytological diagnosis (Low grade squamous intraepithelial lesions -LSIL and high grade squamous intraepithelial lesions -HSIL), as in the Argentinean protocol all HPV + women with abnormal cytologies are referred for colposcopy and biopsy if needed. Secondly, differences between the groups were analyzed using ordinal logistic regression, obtaining odds ratios for having a high, moderate or low score for those with normal cytology when compared to those with abnormal cytology after controlling for age, ever having a partner, and education level.

We used R statistical software (version 3.5.0) for all analysis.

2.5. Ethical Committee approval {#s0035}
-------------------------------

This study was approved by the Ethical Research Committee of the Jujuy Ministry of Health, Argentina (Approval 04/22/2015); written consent was obtained from all women participating in the study.

3. Results {#s0040}
==========

3.1. Women socio-demographic characteristics {#s0045}
--------------------------------------------

A total of 163 HPV + women were invited to participate in the study, all of them accepted and were included in the study sample. Of these, 118 had a current sexual partner and answered items referred to the impact on Sexuality, and 109 had children and answered items regarding regarding impact on their attitudes towards their children ([Table 1](#t0005){ref-type="table"}). Mean age was 38 years (SD = 8 years) and mean number of sexual partners was 1.82. Most women had higher (53.4%) or secondary (36.8%) level of education. Regarding cytology triage, most patients (n = 124; 76.1%) had normal cytologies.Table 1Women socio-demographic characteristics and cytological result (normal/abnormal). Jujuy, 2015--2016.AgeMean38SD8Median35Age by groups30--3476 (46.6%)35--4561 (37.4%)46--5417 (10.4%)55--659 (5.5%)Educational LevelPrimary school16 (9.8%)Secondary school60 (36.8%)College/university87 (53.4%)Number of sexual partners (In life)130 (18.4%)2--3133 (81.6%)Cytological ResultNormal124 (76.1%)Abnormal39 (23.9%)

3.2. Psycho-social impact by domain {#s0050}
-----------------------------------

The measurement of the psycho-social impact of HPV testing in this group of women showed that the mean overall impact score was 2.56, SD: 0.65; median: 2.57. Results for each domain can be seen in [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}. The domain with the highest score was "Worries about cancer and treatment" (mean score: 3.6, SD:0.60, median: 4). Within this domain, the item with the highest score was PSE22: "I am worried about having cervical cancer" (mean 3.81, SD:0.61, median: 4.00). The Sexuality domain showed the second highest mean score (2.50; SD:1, median: 2.33). Within this domain the item with the highest score was PSE11: "After receiving my HPV test results, I worry about infecting my partner during sex" (mean score 2.76, SD:1.23, median: 2.82). The "Uncertainty about information provided by health providers" Domain had the lowest mean score: 2.14, SD: 0.73, median: 2.25. Within this domain, PSE16: "When I received my HPV exam results, I didńt feel comfortable with the way the health workers treated me" had the lowest mean score (1.44, SD:0.92, median: 1.00), which also represented the lowest score among all items of the psycho-social impact scale. The Repercussions on the family (mean score 2.27, SD: 1.24, median: 2.00), and Emotional symptoms (mean score 2.30; SD:0.82, median: 2.31) domains also had relatively low scores. However, in this latter domain, median scores in 3 items was 3 (PSE5: "When I think about my HPV exam results, I feel sad"; PS2: "When I think about my HPV exam results, I dońt feel good about my body", and PS4: "When I think about my HPV exam results, I get nervous"), indicating that half of the women had moderate or high psycho-social impactTable 2Psycho-Estampa scale domains and items (mean. SD. Median). Jujuy, 2015--2016.MeanSDMedianDomain 1: Emotional Symptoms2.30.822.31PSE1"When I think about the results of my HPV exam, I feel sick."2.21.072.00PSE2"When I think about my HPV exam results, I dońt feel good about my body."2.451.163.00PSE3"When I think about my HPV exam results, I feel ashamed."2.41.222.00PSE4"When I think about my HPV exam results, I get nervous."2.661.173.00PSE5"When I think about my HPV exam results, I feel sad."2.721.203.00PSE6"After receiving my HPV exam results, it has been harder for me to concentrate on my daily routine."2.131.202.00PSE7"After learning about my results, I dońt sleep as well as before."1.871.111.00PSE8"After receiving my HPV test results, Ím afraid that my partner will reject me."2.011.221.00Domain 2: Sexuality2.51.002.33PSE9"After receiving my HPV test results, I dońt feel like having sex."2.321.212.00PSE10"After receiving my HPV test results, I have sex less frequently."2.421.292.00PSE11"After receiving my HPV test results, I worry about infecting my partner during sex."2.761.233.00Domain 3: Uncertainty about information provided by health care workers2.140.732.25PSE12"When I think about my HPV exam results, I get angry."2.521.293.00PSE13"As a consequence of my HPV results, Ím worried that I wońt be able to get pregnant."2.531.323.00PSE14"After receiving my HPV results, I feel uncomfortable asking health workers any questions."2.001.251.00PSE15"I thought that the information about HPV that the health workers gave me was confusing."2.071.182.00PSE16"When I received my HPV, exam results, I didńt feel comfortable with the way the health workers treated me."1.440.921.00Domain 4: Repercussions on the family2.271.242.00PSE17"After receiving my HPV results, Ím afraid that I could infect my children."2.081.341.00PSE18"After receiving my positive HPV test results, Ím afraid that at home I might infect other people \[women\] who use the same bathroom that I do."2.401.353.00Domain 5: Worries about cancer and its treatment3.600.604.00PSE19"After receiving my HPV test results, I want to know how I got infected."3.680.734.00PSE20"It worries me to know the Human papillomavirus cannot be cured."3.610.804.00PSE21"It worries me to know that even though I am infected with the Human papillomavirus. Íve been told that I dońt need to be treated for it."3.301.074.00PSE22"Ím worried that I might have cervical cancer."3.810.614.00Table 3Psycho-Estampa scale domains and Total Impact score by socio-demographic variables and cytological Results (mean. SD). Jujuy, 2015--2016.AgeEducational LevelNumber of partners (in life)Cytological result30--3435--4546--5455--65TotalPrimary schoolSecondary schoolTertiary/ universityTotalOneMore than oneTotalAbnormalNormalTotalDomain 1. Emotional SymptomsMean2.302.482.071.802.322.192.302.352.322.292.322.322.622.222.32SD0.780.900.910.780.820.930.820.860.820.890.850.820.840.840.85Valid n76611791631660871633013316339124163Domain 2. SexualityMean2.362.722.532.282.502.742.422.502.502.672.462.502.762.422.50SD0.931.090.991.121.001.110.961.021.001.110.981.001.000.991.00Valid n563917611813446111821971182890118Domain 3. Uncertainty about information provided by HCWMean2.212.101.881.782.142.182.052.142.142.182.092.142.112.112.11SD0.750.630.830.900.730.900.720.710.730.760.730.730.760.730.73Valid n76611791631660871633013316339124163Domain 4. Repercussions on the familyMean2.322.312.122.002.272.412.132.352.272.282.272.282.272.272.28SD1.231.271.331.121.241.251.171.291.241.221.251.241.291.231.24Valid n76611791631660871633013316339124163Domain 5. Worries about cancer and its treatmentMean3.543.663.593.723.603.663.683.533.603.563.613.603.673.583.60SD0.640.560.670.400.600.540.480.680.600.620.600.600.510.630.60Valid n76611791631660871633013316339124163Score globalMean2.412.482.412.162.562.492.412.422.562.432.422.562.572.382.56SD0.630.650.720.710.650.670.590.690.650.690.640.650.630.650.65Valid n76611791631660871633013316339124163

3.3. Psycho-social impact according to Women characteristics {#s0055}
------------------------------------------------------------

[Table 3](#t0015){ref-type="table"} shows scores for the five psycho-social domains and Overall impact according to socio-demographic characteristics of women and cytology diagnosis: Women aged 35--45 had higher scores in most domains, as well as women with abnormal cytology. Higher scores on the Sexuality domain were observed in women with primary school level of education and in those reporting having had only one sexual partner.

Results from the ordinal logistic regression showed a significant association between the odds of having higher negative psycho-social impact and having an abnormal triage cytology and a less strong association with age. The odds of having higher negative psycho-social impact among women with abnormal cytologies was 2.9 (OR: 2.9, 95%CI:1.43--6.07) compared to those with normal cytologies ([Table 4](#t0020){ref-type="table"}). Also, one unit decrease in age (year) was associated with a reduced likelihood of having a higher total psycho-social impact (OR:0.95; p = 0.036, CI = 0.92--0.99).Table 4Ordinal logistic regression to measure association between demographic factors and cytology diagnosis, and Total Impact Score. Jujuy, 2015--2016.FactorsValueStd. ErrorORCIp valueEducation levelPrimary levelRefSecondary level−0.580.600.560.17--1.830.3397Tertiary/University−0.720.590.490.15--1.560.2291Number of partnersOneRefTwo or more0.040.381.040.48--2.240.9121Cytology resultNormalRefAbnormal1.070.372.921.42--6.070.0036Age−0.040.020.950.92--0.990.0363Intercept\[Not at all.little\]\|(Little.Some\]−3.091.140.050.0069(Little.Some\]\|(Some.Much\]−0.771.110.460.4916

No statistically significant associations were found between the scores measured for each specific domain and cytology diagnosis ([Appendix B](#s0090){ref-type="sec"}).

4. Discussion {#s0060}
=============

While several studies have suggested that women can be psycho-socially burdened by a positive HPV test, ([@b0120], [@b0125], [@b0130]) to our knowledge, our study is the first to have quantitatively measured it in a middle-low income setting in the context of population-based HPV-screening: in Jujuy programmatic HPV testing was introduced as the primary screening test in 2012 and has since been the standard of care. ([@b0035]) In Argentina, HPV testing and cytologies are taken in the same screening visit and sent together to the central Cytology/Histology/HPV Laboratory for analysis, so if HPV+, women receive results of HPV testing together with results from cytologies. This has allowed us to measure the impact among women according to their HPV testing and triage (cytology) result.

The highest measure of impact was observed on the "Women worries about cancer and treatment" domain. Several qualitative studies carried out in Latin America have reported results in the same direction. ([@b0080], [@b0085], [@b0090]) In a study carried out in Mexico by Leon Maldonado et al, ([@b0090]) women assumed that HPV was an inevitably serious disease that might be analogous to HIV or necessarily cause cancer. For the authors, misunderstandings about HPV and confusion regarding the testing process itself exacerbated the fears and negative emotions that women often experience when they learn about the sexually transmitted nature of HPV and cervical cancer etiology. In our study, a high impact on this domain was measured even among women who had not been diagnosed with cervical lesions. In line with this finding, a qualitative study that analyzed concerns about HPV among ethnically diverse, low‐income women from the United States found that knowing that HPV does not always progress into cervical cancer does not modify the overall sensations of worry and fear. ([@b0110]) In contrast with our finding, a study carried out in the UK ([@b0130]) found that HPV testing did not add significant psychologic distress to women with normal cytologies; however, in that study scales used to measure distress were not HPV-specific, therefore their results might not be entirely comparable with ours.

HPV + women with normal cytologies are recommended re-screening in 12/18 months, ([@b0020]) this means that they will not have a more conclusive diagnosis until a considerable amount of time has gone by. This waiting might result in increased psycho-social impact, and decreased adherence to re-screening. In Jujuy, it has been shown that only 26% of HPV + women with normal cytologies adhere to repeat screening in the recommended time frame (18 months). ([@b0135]) Subjective reasons including fear, and disease denial ([@b0140]) have been mentioned as the main explanation for abandoning the follow-up and treatment process in cytology-based screening contexts. Given that a significant proportion of these women will be diagnosed with CIN2 + lesions at repeat screening, ([@b0035]) it is very important to devise specific interventions to provide HPV + women with normal cytologies with counseling support aimed at decreasing the psycho-social impact and increasing their capacity to adhere to repeat screening at 18 months.

In our study, in the Sexuality and Emotional Domains the level of the psycho-social impact was between low and moderate (scores between 2 and 3). Evidence has shown that the kind and quality of information that women receive before obtaining the test results have an influence on the psycho-social impact of HPV positivity. ([@b0145], [@b0150]) The above mentioned study carried out in the United States ([@b0110]) found that when women previously know that HPV is a high prevalent infection among young population, they showed significantly lower levels of anxiety than those who did not know. In our study we did not evaluate the quality of the information received during the screening visit and/or consultation to receive the HPV test results, but we ensured that health providers informing women had previously participated in training organized by the National Program on Cervical Cancer Prevention on how to communicate HPV results. Also, specific communication materials were produced both for women and providers, highlighting the key message that HPV was a highly prevalent infection which could have been contracted many years ago. ([@b0155]) A qualitative study among women HPV + or diagnosed with CIN ([@b0085]) showed that feelings of fear and anguish were related to how they were treated during the consultation and the information provided or omitted by doctors. Other studies carried out in contexts of cytology-based screening also showed that insufficient interaction with health professionals can result in women's higher stress and anxiety. ([@b0160], [@b0095], [@b0100]) It is possible that the information provided by the gynecology service at the hospital, and the quality of the interaction with health professionals in charge of providing results in our study had contributed to reduce the impact on these domains. This is supported by the fact that the item measuring impact related to the "Information received during the consultation" was the one with the lower score in the whole scale. The low score on this information-related item also suggests that even in cases when women consider that they receive clear information, this might not be enough to reduce the level of impact regarding the Fear of cancer and treatment domain, which might need specific counseling strategies for its reduction.

The level of overall impact found in our study was moderate and was influenced by particularly low scores in the Uncertainty about information provided by health providers domain. The interdependence between uncertainty about the information provided by health providers and the overall psycho-social impact could imply that among women screened at other services and by other health professionals, the psycho-social impact might be higher.

A study carried out in Korea ([@b0165]) to measure the psycho-social impact of HPV related diseases also found a moderate overall impact. However, the Korean study used the HPV Impact Profile (HIP) scale, developed by ROCHE to measure the impact on HPV-related disease, ([@b0170]) which is not specific to the impact of HPV screening positivity. For example, the HIP includes questions regarding genital warts and therefore, its final score is not entirely comparable with scores obtained with the Psycho-Estampa scale. Andreassen et al, ([@b0175]) who carried out a study in the context of population-based HPV-testing found no negative impact among HPV + women; however they used the Patient Health Questionnaire‐4 (PHQ‐4), a 4-item scale whose main objective is to provide a brief measurement of depression and anxiety; therefore, no item in that scale is worded as to detect the psycho-social impact of HPV-testing. Also, they measured impact 4--24 months after women had been informed about their last screening test result, so there might be a time effect that should also be considered.

The overall level of psycho-social impact was associated to the cytology diagnosis, being women with abnormal triage cytolologies those with an increased probability of having a higher psycho-social impact. A study carried in the UK that used the HIP scale ([@b0170]) to measure impact among women with abnormal cytologies also found a significant reduced impact among women with normal cytologies, but women in that study had not been HPV tested and their HPV status was unknown. ([@b0075]) A qualitative study carried out in Dublin by ÓConnor et al, ([@b0180]) found that factors that influenced whether women experienced negative emotional responses regarding HPV-infections were mainly dominated by concerns over abnormal cytology or diagnosis of CIN. However, in the sample included in the study by ÓConnor et al only six women were HPV + while 11 women were HPV negative; in addition, women had been HPV-tested up to 6 months ago; therefore, their responses might have been affected by time elapsed since diagnosis. Our study measured the impact one week after having received the results, so we think that we were able to measure the immediate psycho-social impact of a positive HPV result received as part of a routine, programmatic HPV-based screening.

We used a measurement instrument (The Psycho-Estampa scale) specifically designed and validated to measure the impact of HPV-testing among Latin American women. This is the first time that data on the impact of HPV-testing is measured using the Psycho-Estampa scale. Other studies ([@b0165]) have used the HIP scale and the PHQ-4 scale. ([@b0170]) As above-mentioned, the HIP scale has been developed to measure impact of various HPV-related diseases. Also, many items in the HIP scale are worded in a way that answers given by women might be referring to the impact of the gynecologic consultation experience rather than to of the impact derived from the result of the test in itself. Regarding the study that used the PHQ‐4 scale ([@b0175]) women were interviewed 4--24 months after they had been informed about their last screening test result, so a time effect might also affect comparability of results. Also, as mentioned above, no item in that scale is worded as to detect the psycho-social impact of HPV-testing.

Our study is the first to use the Psycho-estampa scale, a measurement tool specifically designed to measure the psycho-social impact of HPV-positivity among subjects who are screened with HPV-testing provided as primary screening.

Our study has a main limitation, which is that we measured impact on a sample of women attending a main hospital in San Salvador de Jujuy, the provincial capital city. Therefore, impact measured in our sample may not be representative of the impact experienced by women receiving results in other health centers, and in other areas, i.e. rural areas. Also, the majority of women were highly educated, whereas at population level 42% of women living in Jujuy province have up to primary level of education. ([@b0185]) It was certainly a population screened in the context of routine screening, so the impact women experienced happened with HPV testing provided in real world, programmatic conditions. Further research expanding these findings to other groups of HPV-tested women will help clarify these issues.

Our results suggest that there is a need for interventions aimed at reducing the psycho-social impact of HPV-testing. WHO recommends counseling as a strategy for inter-personal communication between the health provider and the woman, as it will allow women to become more informed and knowledgeable about HPV and cervical cancer prevention, will allow them to discuss sensitive topics, such as sexuality, disease, and death, and will encourage them to adopt preventive practices. ([@b0190]) Therefore, it is important to develop strategies that include counseling for providing HPV-results so they can be implemented and evaluated as a tool to reduce the psycho-social impact of HPV-testing.

5. Conclusions {#s0065}
==============

HPV testing is the current recommended standard of care for cervical cancer screening, but its reduced specificity not only affects the diagnosis workload at colposcopy centers but might have a negative social and psychological impact on women lives. This is the first study to quantitatively measure the psycho-social impact of HPV positivity among women screened with HPV testing in Latin America. We found that the psycho-social impact was particularly high in the Fear of Cancer and Treatment Domain. The overall psycho-social impact was moderate, but it was increased among women with abnormal triage cytologies. As the psycho-social impact of HPV positivity can not only result in psychological distress but it can also influence women adherence to follow-up recommendations and treatment, specific counseling interventions to reduce it are needed.
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